Having trouble accessing articles? Reset your cache.

AI play Healx raises $56M to repurpose drugs for rare disease

How Healx is tackling rare diseases using AI and input from patient groups

Bolstered by a $56 million series B round, Healx is taking human bias out of drug discovery by leaving most strategic and technical decisions up to AI. Its approach is to use an AI-powered platform to identify tractable rare diseases and drugs that could be repurposed to treat them.

The series B, announced Wednesday and led by Atomico, will help fund Healx Ltd.’s first clinical trial,

Read the full 651 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers